"is being driven by robust demand growth and ongoing inventory reduction, alongside regulatory tightening, including the shutdown of a major Chinese lithium mine by Contemporary Amperex Technology Co. Ltd. (CATL) and new government measures aimed at preventing producers from selling lithium at unsustainably low prices. The increased recognition of lithium as a critical mineral, combined with Western concerns over China's control of global supply chains, is bolstering the sector outside of China."
"In the 64-week OASIS 4 study of 307 adults without diabetes, participants taking the pill alongside lifestyle changes lost an average of 16.6% of body weight, compared with 2.7% for placebo. Over a third (34.4%) achieved at least 20% weight loss, versus 2.9% for placebo,"
Albemarle climbed from about $50 in April to $145.38 and rose another $4.15 as lithium demand expectations and supply tightening boost prices. Ganfeng’s chairman projected demand could rise 30% to 50% next year. Sprott attributes the lithium rebound to robust demand growth, inventory reduction, regulatory tightening including a CATL-related mine shutdown, and policy measures preventing unsustainably low pricing, while Western concerns about Chinese supply control strengthen non-China producers. Albemarle trades at $145.38 with an initial test target of $160. Novo Nordisk’s oral Wegovy won approval, shows substantial weight loss in OASIS 4, and NVO trades at $48.10 with a $55 target. Viking Therapeutics is seeing upside related to Novo Nordisk news and recently completed enrollment in a study.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]